A Peptoid “Antibody Surrogate” That Antagonizes VEGF Receptor 2 Activity
- 1 April 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 130 (17), 5744-5752
- https://doi.org/10.1021/ja711193x
Abstract
We report a two-color, cell-based screen to identify specific receptor-binding compounds in a combinatorial library of peptoids displayed on beads. We apply this strategy to the isolation of vascular endothelial growth factor receptor 2 (VEGFR2)-binding peptoids. A dimeric derivative of one of these lead compounds is shown to be an antagonist of VEGFR2 activity both in vitro and in vivo. This methodology provides a potentially general route to synthetic molecules that bind integral membrane receptors with affinities and specificities similar to those of antibodies, but which are far smaller and easier to make and manipulate.Keywords
This publication has 42 references indexed in Scilit:
- Structural Proof of a Dimeric Positive Modulator Bridging Two Identical AMPA Receptor-Binding SitesChemistry & Biology, 2007
- VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastasesProceedings of the National Academy of Sciences, 2007
- Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivoBiochemical and Biophysical Research Communications, 2007
- Transformation of Low-Affinity Lead Compounds into High-Affinity Protein Capture AgentsChemistry & Biology, 2004
- The promise of targeted therapy: cancer drugs become more specific.Cleveland Clinic Journal of Medicine, 2004
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Therapeutic cancer targeting peptidesPeptide Science, 2002
- Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced ImmunogenicityHybridoma, 2000
- Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)glycine Peptoid LibraryJournal of Medicinal Chemistry, 1994
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993